WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005013802) TREFOIL FACTOR 3 (TFF3) AS A TARGET FOR ANTI-CANCER THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/013802    International Application No.:    PCT/US2004/025508
Publication Date: 17.02.2005 International Filing Date: 05.08.2004
IPC:
A61K 48/00 (2006.01)
Applicants: CHIRON CORPORATION [US/US]; 4560 Horton Street, M/S R338, Emeryville, CA 94608-2916 (US) (For All Designated States Except US).
JANATPOUR, Mary, J. [US/US]; (US) (For US Only).
GARCIA, Pablo [CL/US]; (US) (For US Only).
REINHARD, Christoph [DE/US]; (US) (For US Only)
Inventors: JANATPOUR, Mary, J.; (US).
GARCIA, Pablo; (US).
REINHARD, Christoph; (US)
Agent: ALEXANDER, Lisa, E.; Corporate Patent Counsel, 4560 Horton Street, M/S R338, Emeryville, CA 94608-2916 (US)
Priority Data:
60/493,173 07.08.2003 US
60/498,438 28.08.2003 US
Title (EN) TREFOIL FACTOR 3 (TFF3) AS A TARGET FOR ANTI-CANCER THERAPY
(FR) PEPTIDE EN TREFLE TFF3 UTILISE COMME CIBLE DANS LA THERAPIE ANTICANCEREUSE
Abstract: front page image
(EN)The present invention is directed to methds of treating and preventing cancer, such as cancer characterized by differential expression of trefoil factor 3 (TFF3). The methods include administering to a patient an agent that modulates TFF3 activity or expression. The present invention is further directed to reducing the physiological effects of TFF3 expression in cells, including inhibiting cell motility and resistance to apoptosis. Oligonucleotides and antibodies that can modulate expression or activity of TFF3 are also provided.
(FR)L'invention concerne des méthodes de prévention et de traitement des cancers se caractérisant par une expression différentielle du peptide en trèfle TFF3. Les méthodes selon l'invention consistent à administrer à un patient un agent modulant l'activité ou l'expression du TFF3. La présente invention concerne également l'atténuation des effets physiologiques de l'expression du TFF3 dans des cellules, notamment de l'inhibition de la motilité cellulaire et de la résistance à l'apoptose. L'invention concerne encore des oligonucléotides et des anticorps pouvant moduler l'expression ou l'activité du TFF3.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)